Russias drugs exports in January November 2017 amounted to 19 billion rubles

12 January 2018

GMP News

In the first 11 months of 2017, the exports of medicinal products from Russia (excluding the shipments to EAEU) reached 19.0 billion rubles (including the customs duties). This means that, when calculated in the Russian currency, the increase over the same period of 2016 was only 0.4%. However, the mere fact of positive dynamics is quite encouraging, as the results for January-October were much gloomier (at that time, the long-term growth rate was -2.2%).

The active efforts of exporters reversed the situation in November 2017. For that month, the total exports of medicinal products from Russia reached 2.3 billion rubles, an increase was 23% in ruble terms. Although this was not a record-breaking result, it is still quite outstanding, since better dynamics have been demonstrated by exporters only in January 2017, when the shipments increased by 58%.

In physical terms, the exports in November 2017 amounted to 70.8 million packages, a 22% increase year over year. Moreover, throughout the year, the general dynamics in physical terms can be described as rather successful. Despite occasional downturns reported, for example, for February when the exports in terms of shipped packages fell by 38%, the overall results for the first 11 months of 2017 have been markedly positive (+7.3%). Since the beginning of 2017, the total exports of medicinal products from Russia reached 536.4 million packages.

Previous publication Next publication

Media Center

  • 22 March 2018

    GMP Inspection practice: a case for global benchmarking, convergence and mutual reliance/recognition

    In 1969 the global agreement on the Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce was proposed by WHO. The aim was to facilitate international trade in pharmaceuticals through mutual recognition of GMP inspection results. Today, almost 50 years later, up to one hundred countries conduct foreign inspections. As a result a manufacturing site well established, might be inspected  many times in one year by local and different foreign authorities. This leads to duplication of work and waste of recourses both by regulators and industry.

  • 22 March 2018

    Kaluga is expected to complete its program for radiopharmaceuticals in two years

    Kaluga pharmaceutical cluster recently increased the number of locally manufactured drugs from 65 to 154. The Governor Anatoly Artamonov expects that the region needs 2 more years to complete its import substitution program for radiopharmaceuticals, reported Kaluzhskaya Nedelya, a local newspaper.

  • 21 March 2018

    Blockchain technology has a special potential to confront counterfeit drugs

    DHL has released a trend report in cooperation with Accenture, a leading global technology consultant, on blockchain technology’s potential to transform the logistics industry. The report includes initial findings on a working prototype developed by DHL and Accenture, which tracks pharmaceuticals from the point of origin to the consumer, preventing tampering and errors.

  • 20 March 2018

    Russia establishes its National Quality Infrastructure Council

    On March 14, Denis Manturov, the Russian Minister of Industry and Trade, chaired a meeting of the State Commission on Counteraction to Illegal Circulation of Industrial Products. The Minister said that, ensuring the “market purity” would require, in addition to providing more preferences for entrepreneurs operating strictly within the legal field, to guarantee to potential consumers that they purchase genuine rather than counterfeit and falsified products.

Read more